Renal Cancer - Results from #5320

Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma. March 9, 2017

Neutrophil-to-lymphocyte ratio as an independent predictor for survival in patients with localized clear cell renal cell carcinoma after radiofrequency ablation: a propensity score matching analysis. March 9, 2017

Patterns of care among patients receiving sequential targeted therapies for advanced renal cell carcinoma: A retrospective chart review in the USA March 8, 2017

Intracrine androgen biosynthesis in renal cell carcinoma March 8, 2017

Hereditary Renal Tumor Syndromes: Update on Diagnosis and Management. March 8, 2017

Surgical Management and Outcome of Renal Cell Carcinoma with Inferior Vena Cava Tumor Thrombus. March 8, 2017

Renal cell carcinoma: Atypical metastasis to inguinal lymph nodes March 7, 2017

Outcomes and Drug Costs of Sunitinib Regimens for Metastatic Renal Cell Carcinoma: A Provincial Population-Based Study March 7, 2017

Outcomes of Patients With Metastatic Renal Cell Carcinoma and Bone Metastases in the Targeted Therapy Era March 7, 2017

Prediction of Everolimus Toxicity and Prognostic Value of Skeletal Muscle Index in Patients With Metastatic Renal Cell Carcinoma March 7, 2017

Correlation of c-Met Expression and Outcome in Patients With Renal Cell Carcinoma Treated With Sunitinib March 6, 2017

Clinical Pharmacokinetic and Pharmacodynamic Profile of Lenvatinib, an Orally Active, Small-Molecule, Multitargeted Tyrosine Kinase Inhibitor March 6, 2017

Are Quality-Adjusted Life Years a Good Proxy Measure of Individual Capabilities? March 3, 2017

The prognostic value of the neutrophil-lymphocyte ratio in renal oncology: A review March 3, 2017

FDA Approval Summary: Nivolumab in Advanced Renal Cell Carcinoma After Anti-Angiogenic Therapy and Exploratory Predictive Biomarker Analysis March 2, 2017

Cabozantinib targets bone microenvironment modulating human osteoclast and osteoblast functions March 2, 2017

PD-L1 Studies Across Tumor Types, its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors March 2, 2017

Benefit of adjuvant immunotherapy in renal cell carcinoma: A myth or a reality? March 1, 2017

Nivolumab induced myxedema crisis March 1, 2017

[Immunotherapy for the treatment of patients with genitourinary cancers: Review and perspectives] March 1, 2017

Page 267 of 456